ITMI20030151A1 - USE OF SELECTIVE MGLU5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROMUSCULAR DYSFUNCTIONS OF THE LOWER URINARY TRACT. - Google Patents

USE OF SELECTIVE MGLU5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROMUSCULAR DYSFUNCTIONS OF THE LOWER URINARY TRACT.

Info

Publication number
ITMI20030151A1
ITMI20030151A1 IT000151A ITMI20030151A ITMI20030151A1 IT MI20030151 A1 ITMI20030151 A1 IT MI20030151A1 IT 000151 A IT000151 A IT 000151A IT MI20030151 A ITMI20030151 A IT MI20030151A IT MI20030151 A1 ITMI20030151 A1 IT MI20030151A1
Authority
IT
Italy
Prior art keywords
treatment
receptor antagonists
urinary tract
lower urinary
mglu5 receptor
Prior art date
Application number
IT000151A
Other languages
Italian (it)
Inventor
Amedeo Leonardi
Elena Poggesi
Rodolfo Testa
Original Assignee
Recordati Ind Chimica E Farma Ceutica S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ind Chimica E Farma Ceutica S P A filed Critical Recordati Ind Chimica E Farma Ceutica S P A
Priority to IT000151A priority Critical patent/ITMI20030151A1/en
Priority to US10/768,953 priority patent/US20040215284A1/en
Priority to EP04706676A priority patent/EP1599204A2/en
Priority to PCT/EP2004/000951 priority patent/WO2004067002A2/en
Priority to TW093102163A priority patent/TW200418798A/en
Priority to JP2006501708A priority patent/JP2006516587A/en
Publication of ITMI20030151A1 publication Critical patent/ITMI20030151A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT000151A 2003-01-30 2003-01-30 USE OF SELECTIVE MGLU5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROMUSCULAR DYSFUNCTIONS OF THE LOWER URINARY TRACT. ITMI20030151A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IT000151A ITMI20030151A1 (en) 2003-01-30 2003-01-30 USE OF SELECTIVE MGLU5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROMUSCULAR DYSFUNCTIONS OF THE LOWER URINARY TRACT.
US10/768,953 US20040215284A1 (en) 2003-01-30 2004-01-29 Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
EP04706676A EP1599204A2 (en) 2003-01-30 2004-01-30 Selective mglu5 antagonists for treatment of neuromuscular dysfunction of the lower urinary tract
PCT/EP2004/000951 WO2004067002A2 (en) 2003-01-30 2004-01-30 SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT
TW093102163A TW200418798A (en) 2003-01-30 2004-01-30 Selective mGlu5 antagonists for treatment of neuromuscular dysfunction of the lower urinary tract
JP2006501708A JP2006516587A (en) 2003-01-30 2004-01-30 Selective mGlu5 antagonists for the treatment of neuromuscular disorders of the lower urinary tract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000151A ITMI20030151A1 (en) 2003-01-30 2003-01-30 USE OF SELECTIVE MGLU5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROMUSCULAR DYSFUNCTIONS OF THE LOWER URINARY TRACT.

Publications (1)

Publication Number Publication Date
ITMI20030151A1 true ITMI20030151A1 (en) 2004-07-31

Family

ID=32800691

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000151A ITMI20030151A1 (en) 2003-01-30 2003-01-30 USE OF SELECTIVE MGLU5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROMUSCULAR DYSFUNCTIONS OF THE LOWER URINARY TRACT.

Country Status (5)

Country Link
EP (1) EP1599204A2 (en)
JP (1) JP2006516587A (en)
IT (1) ITMI20030151A1 (en)
TW (1) TW200418798A (en)
WO (1) WO2004067002A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
ATE445399T1 (en) 2004-03-22 2009-10-15 Lilly Co Eli PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS
BRPI0511678A (en) 2004-06-01 2008-01-08 Hoffmann La Roche pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
EP1948667B1 (en) * 2005-11-08 2012-04-11 F. Hoffmann-La Roche AG Thiazolo[4,5-c]pyridine derivatives as mglu5 receptor antagonists
TWI417095B (en) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
SI2178858T1 (en) 2007-08-02 2012-03-30 Recordati Ireland Ltd Novel heterocyclic compounds as mglu5 antagonists
JP5366269B2 (en) 2007-09-14 2013-12-11 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 1,3-disubstituted 4- (allyl-X-phenyl) -1H-pyridin-2-one
CN101801930B (en) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
SG10201402250TA (en) 2009-05-12 2014-07-30 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011962A (en) 2009-05-12 2012-02-28 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors.
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ES2552879T3 (en) 2010-11-08 2015-12-02 Janssen Pharmaceuticals, Inc. 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (en) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
HUE053734T2 (en) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
EA201891617A3 (en) 2014-01-21 2019-04-30 Янссен Фармацевтика Нв COMBINATIONS CONTAINING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR 2 SUBTIPES AND THEIR APPLICATION
BR112017028125A2 (en) 2015-06-23 2018-08-28 Kissei Pharmaceutical Co., Ltd. derived from pyrazole or pharmaceutically acceptable salt of the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601680D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
IT1293807B1 (en) * 1997-08-01 1999-03-10 Recordati Chem Pharm 1- (N-PHENYLAMINOALKYL) PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING
ES2251512T3 (en) * 2000-08-31 2006-05-01 F. Hoffmann-La Roche Ag DERIVATIVES OF QUINAZOLINE AS AN ADRENERGIC ANTAGONIST ALFA-1.
KR100515549B1 (en) * 2000-12-04 2005-09-20 에프. 호프만-라 로슈 아게 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
EP2033951A3 (en) * 2002-02-01 2009-12-23 Euro-Celtique S.A. 2-Piperazine-pyridines useful for treating pain
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
CA2491079C (en) * 2002-06-28 2011-10-04 Donald J. Kyle Therapeutic piperazine derivatives useful for treating pain

Also Published As

Publication number Publication date
EP1599204A2 (en) 2005-11-30
WO2004067002A3 (en) 2004-11-25
TW200418798A (en) 2004-10-01
WO2004067002A2 (en) 2004-08-12
JP2006516587A (en) 2006-07-06

Similar Documents

Publication Publication Date Title
ITMI20030151A1 (en) USE OF SELECTIVE MGLU5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROMUSCULAR DYSFUNCTIONS OF THE LOWER URINARY TRACT.
NL1032713A1 (en) Histamine 3 receptor antagonists.
DK1638969T3 (en) CGRP receptor antagonists
DK1720859T3 (en) Chemokine receptor antagonists
IL178334A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
SI1729753T1 (en) Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
IS8119A (en) Dense N-heterocyclic compounds and their use as CRF receptor antagonists
ATE420083T1 (en) UREA DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS FOR PAIN TREATMENT
DK1682142T3 (en) M3-muscarinic acetylcholine receptor antagonists
SMAP200600024A (en) 2,6-Biseteroaryl-4-aminopirimidine as adenosine receptor antagonists
NO20055525D0 (en) Tissue Protective Cytokine Receptor Complex Assay for Identifying Tissue Protective Compounds and Uses thereof
GB0504828D0 (en) Therapeutic agents
DK1711465T3 (en) Hydroisoindoline tachykinic receptor antagonists
DE602004021250D1 (en) 2-ALKINYL- AND 2-ALKENYL-PYRAZOLO-Ä4,3-EÜ-1,2,4-TRIAZOLO-Ä1,5-CÜ-PYRIMIDINADENOSINE A2A RECEPTOR ANTAGONISTS
IL184233A0 (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
FI20060188A (en) Modified IL-4 mutein receptor antagonists
DK1463759T3 (en) Ligand for the G-protein-coupled receptor GPR43 and uses thereof
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
ATE425161T1 (en) MERCAPTOIMIDAZOLE AS CCR2 RECEPTOR ANTAGONISTS
DE602005010577D1 (en) MERCAPTOIMIDAZOLE AS CCR2 RECEPTOR ANTAGONISTS
ITBO20030521A1 (en) ENDOSCOPE FOR OCULISTIC USE.
NO20034837L (en) CRF receptor antagonists
ITBO20040077A1 (en) EQUIPMENT FOR THE COLLECTION OF SHAPED IRONS.
ITMI20031378A1 (en) NEW 3-REPLACED INDOLID LIGANDS OF ORL-1 RECEPTOR.
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia